Evidence map›Paper›PMID 25933429›Full record

ArticlePloS one2015

Health providers' perceptions of clinical trials: lessons from Ghana, Kenya and Burkina Faso.

Vibian Angwenyi, Kwaku-Poku Asante, Abdoulaye Traoré, Lawrence Gyabaa Febir, Charlotte Tawiah, Anthony Kwarteng, Alphonse Ouédraogo, Sodiomon Bienvenue Sirima, Seth Owusu-Agyei, Egeruan Babatunde Imoukhuede and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. COVID-19 vaccine research and development: ethical issues.Tropical medicine & international health : TM & IH · 2021
    Review
  6. Article
  7. Article
  8. Article
  9. Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 5 countries.

Vibian AngwenyiDepartment of Public Health Research, KEMRI/Wellcome Trust Research Programme (KWTRP), P.O. Box, 230-80108, Kilifi, Kenya.
Kwaku-Poku AsanteKintampo Health Research Centre (KHRC), P.O. Box 200, Kintampo, Ghana.
Abdoulaye TraoréCentre National de Recherche et de Formation sur le Paludisme (CNRFP), 01 BP 2208, Ouagadougou 01, Burkina Faso.
Lawrence Gyabaa FebirKintampo Health Research Centre (KHRC), P.O. Box 200, Kintampo, Ghana.
Charlotte TawiahKintampo Health Research Centre (KHRC), P.O. Box 200, Kintampo, Ghana.
Anthony KwartengKintampo Health Research Centre (KHRC), P.O. Box 200, Kintampo, Ghana.
Alphonse OuédraogoCentre National de Recherche et de Formation sur le Paludisme (CNRFP), 01 BP 2208, Ouagadougou 01, Burkina Faso.
Sodiomon Bienvenue SirimaCentre National de Recherche et de Formation sur le Paludisme (CNRFP), 01 BP 2208, Ouagadougou 01, Burkina Faso.
Seth Owusu-AgyeiKintampo Health Research Centre (KHRC), P.O. Box 200, Kintampo, Ghana.
Egeruan Babatunde ImoukhuedeEuropean Vaccine Initiative (EVI),Universitäts Klinikum Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
Jayne WebsterDisease Control Department, London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, London, United Kingdom.
Daniel ChandramohanDisease Control Department, London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, London, United Kingdom.
Sassy MolyneuxDepartment of Public Health Research, KEMRI/Wellcome Trust Research Programme (KWTRP), P.O. Box, 230-80108, Kilifi, Kenya; The Ethox Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, United Kingdom; The Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, United Kingdom.
Caroline JonesDepartment of Public Health Research, KEMRI/Wellcome Trust Research Programme (KWTRP), P.O. Box, 230-80108, Kilifi, Kenya; Disease Control Department, London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, WC1E 7HT, London, United Kingdom; The Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, United Kingdom.
Kintampo Health Research Centre · GHCentre National de Recherche et de Formation sur le Paludisme · BFKenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical trials conducted in Africa often require substantial investments to support trial centres and public health facilities. Trial resources could potentially generate benefits for routine health service delivery but may have unintended consequences. Strengthening ethical practice requires understanding the potential effects of trial inputs on the perceptions and practices of routine health care providers. This study explores the influence of malaria vaccine trials on health service delivery in Ghana, Kenya and Burkina Faso.

methodsWe conducted: audits of trial inputs in 10 trial facilities and among 144 health workers; individual interviews with frontline providers (n=99) and health managers (n=14); and group discussions with fieldworkers (n=9 discussions). Descriptive summaries were generated from audit data. Qualitative data were analysed using a framework approach.

resultsFacilities involved in trials benefited from infrastructure and equipment upgrades, support with essential drugs, access to trial vehicles, and placement of additional qualified trial staff. Qualified trial staff in facilities were often seen as role models by their colleagues; assisting with supportive supervision and reducing facility workload. Some facility staff in place before the trial also received formal training and salary top-ups from the trials. However, differential access to support caused dissatisfaction, and some interviewees expressed concerns about what would happen at the end of the trial once financial and supervisory support was removed.

conclusionClinical trials function as short-term complex health service delivery interventions in the facilities in which they are based. They have the potential to both benefit facilities, staff and communities through providing the supportive environment required for improvements in routine care, but they can also generate dissatisfaction, relationship challenges and demoralisation among staff. Minimising trial related harm and maximising benefits requires careful planning and engagement of key actors at the outset of trials, throughout the trial and on its' completion.

Indexed as

Clinical Trials as TopicHealth Knowledge, Attitudes, PracticeHealth PersonnelBurkina FasoDelivery of Health CareGhanaHealth FacilitiesHumansKenyaMalaria VaccinesMalaria Vaccines

Identifiers

PMID25933429
PMCPMC4416706
OpenAlexW2063843882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.